This indicates an exciting area for drug development, as minimal patient side effects may be seen, and, for the first time, a monoclonal ROR1 targeting antibody did not observe any off-target toxicity in preclinical studies and is now available in a phase I trial for Chronic Lymphocytic Leukemia [30]. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.